Article Text

other Versions

PDF
Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: A randomized, crossover, double-blind, placebo controlled inpatient trial.
  1. Catherine Willmott (catherine.willmott{at}med.monash.edu.au)
  1. Monash University, Australia
    1. Jennie Ponsford (jennie.ponsford{at}med.monash.edu.au)
    1. Monash University, Australia

      Abstract

      Objectives: Most previous studies evaluating use of methylphenidate following traumatic brain injury (TBI) have been conducted many years post-injury. This study evaluated the efficacy of methylphenidate in facilitating cognitive function in the inpatient rehabilitation phase.

      Methods: 40 participants with moderate-severe TBI (Mean = 68 days post-injury) were recruited into a randomised, crossover, double-blind, placebo controlled trial. Methylphenidate was administered at a dose of 0.3mg/kg bd and lactose in identical capsules served as placebo. Methylphenidate and placebo administration was randomized in a crossover design across six sessions over a two week period. Primary efficacy outcomes were neuropsychological tests of attention.

      Results: No participants were withdrawn due to side-effects or adverse events. Methylphenidate significantly increased speed of information processing on the Symbol Digit Modalities Test (95% CI .30 to 2.95, Cohen’s d = .39, p = .02), Ruff 2 & 7 Test – Automatic Condition (95% CI 1.38 to 6.12, Cohen’s d = .51, p = .003), Simple Selective Attention Task (95% CI -58.35 to -17.43, Cohen’s d = .59, p = .001) and Dissimilar Compatible (95% CI -70.13 to -15.38, Cohen’s d = .51, p = .003) and Similar Compatible (95% CI -74.82 to -19.06, Cohen’s d = .55, p = .002) conditions of the Four Choice Reaction Time Task. Those with more severe injuries and slower baseline information processing speed demonstrated a greater drug response.

      Conclusions: Methylphenidate enhances information processing speed in the inpatient rehabilitation phase following TBI. This trial is registered with the Australian New Zealand Clinical Trials Registry (12607000503426).

      Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.